Accept Refuse

EUR-Lex Access to European Union law

Back to EUR-Lex homepage

This document is an excerpt from the EUR-Lex website

Document C2008/200/04

Prior notification of a concentration (Case COMP/M.5247 — Daiichi Sankyo/Ranbaxy Laboratories) — Candidate case for simplified procedure Text with EEA relevance

OJ C 200, 6.8.2008, p. 8–8 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

6.8.2008   

EN

Official Journal of the European Union

C 200/8


Prior notification of a concentration

(Case COMP/M.5247 — Daiichi Sankyo/Ranbaxy Laboratories)

Candidate case for simplified procedure

(Text with EEA relevance)

(2008/C 200/04)

1.

On 30 July 2008, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Daiichi Sankyo Company, Limited (‘DS’, Japan) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of Ranbaxy Laboratories Limited, India (‘Ranbaxy’, India), by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

for DS: pharmaceutical company,

for Ranbaxy: pharmaceutical company.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5247 — Daiichi Sankyo/Ranbaxy Laboratories, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel


(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.


Top